Costs of inpatient treatment for multi‐drug‐resistant tuberculosis in South Africa
Open Access
- 21 November 2012
- journal article
- research article
- Published by Wiley in Tropical Medicine & International Health
- Vol. 18 (1) , 109-116
Abstract
Background: In South Africa, patients with multi‐drug‐resistant tuberculosis (MDR‐TB) are hospitalised from MDR‐TB treatment initiation until culture conversion. Although MDR‐TB accounts for <3% of incident TB in South Africa, 55% of the public sector TB budget is spent on MDR‐TB. To inform new strategies for MDR‐TB management, we estimated the per‐patient cost (USD 2011) of inpatient MDR‐TB treatment.Methods: All resources used by patients admitted to the MDR‐TB hospital with confirmed MDR‐TB from March 2009 to February 2010 were abstracted from patient records for up to 12 months after initial admission or until the earliest of final discharge, abscondment or death. Costs of hospital stay/day were estimated from hospital expenditure records and costs for drugs, laboratory tests, radiography and surgery from public sector sources. 133 patients met study inclusion criteria of whom 121 had complete cost records.Results: By 12 months, 86% were discharged with culture conversion, 8% died in hospital, 2% were still admitted, and 3% had absconded. The mean hospital stay was 105 days. The mean total cost per patient was $17 164, of which 95% were hospitalisation costs (buildings, staff, etc.) and ≤ 2% each for MDR‐TB drugs ($380); TB laboratory tests, including drug susceptibility testing ($236); and other costs.Conclusions: The inpatient cost per patient treated for MDR‐TB is more than 40 times the cost of treating drug‐susceptible TB in South Africa. There is potential for substantial cost savings from improved management of drug‐susceptible TB and shifting to a model of decentralised, outpatient MDR‐treatment.Keywords
This publication has 9 references indexed in Scilit:
- The Impact and Cost of Scaling up GeneXpert MTB/RIF in South AfricaPLOS ONE, 2012
- A Systematic Review of the Cost and Cost Effectiveness of Treatment for Multidrug-Resistant TuberculosisPharmacoEconomics, 2012
- Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007–2010Bulletin of the World Health Organization, 2011
- Outcomes of Multi-Drug Resistant Tuberculosis (MDR-TB) among a Cohort of South African Patients with High HIV PrevalencePLOS ONE, 2011
- Culture Conversion Among HIV Co-Infected Multidrug-Resistant Tuberculosis Patients in Tugela Ferry, South AfricaPLOS ONE, 2011
- The high cost of second-line antiretroviral therapy for HIV/AIDS in South AfricaAIDS, 2010
- HIV Coinfection in Multidrug- and Extensively Drug-Resistant Tuberculosis Results in High Early MortalityAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Is HIV Infection a Risk Factor for Multi-Drug Resistant Tuberculosis? A Systematic ReviewPLOS ONE, 2009
- Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysisThe Lancet Infectious Diseases, 2009